ÃÛÑ¿´«Ã½

Available for over a year

In this episode of The Evidence, Claudia Hammond and a panel of experts discuss the latest evidence on weight loss injections. Medications such as Ozempic and Wegovy are proven to be highly effective for weight management. They are also increasingly being found to treat other conditions and reduce the risk of disease, promising health benefits far beyond the treatment of obesity. But these drugs generally need to be continued for weight loss to be maintained, so there are big questions to be answered about their use and significant challenges to overcome around access and availability.  In front of a live audience at Wellcome Collection in London, Claudia and her guests explore the potential and negatives of weight loss injections and ask whether they really are the next wonder drug. On stage with Claudia are Professor John Wilding, a consultant physician at University Hospital Aintree in Liverpool and lead clinical researcher; geneticist Giles Yeo, a professor of Molecular Neuroendocrinology at the MRC Metabolic Diseases Unit at the University of Cambridge; Dr Adrian Brown, a specialist weight management dietician and senior research fellow/lecturer at University College London and consultant endocrinologist Professor Barbara McGowan, who is Professor of Endocrinology and Diabetes at Guy’s and St. Thomas’ Hospital in London. Producer: Helena Selby Sound engineers: Emma Harth and Duncan Hannant (Photo: Woman using Semaglutide injection pen. Credit: Munro/Getty Images) Declaration of interests: Professor John Wilding has advised several companies involved in development of treatments for obesity and diabetes and been an investigator for related clinical trials; consultancy fees for this work are paid to his employer. Professor Giles Yeo has received grant funding from Novo Nordisk and currently has grant funding from AMGEN. He consults for both Novo Nordisk and Eli Lilly and Company. Dr Adrian Brown has received researcher-led grant funding from Novo Nordisk and has received honoraria and speaker fees from Novo Nordisk and Eli Lilly. He is on the Medical Advisory Board and is a shareholder of Reset Health Ltd. Professor Barbara McGowan has received speaker fees or consultancy fees from Novo Nordisk, Lilly, Boehringer Ingelheim, Astra Zeneca and Janssen. She was a recipient of a Novo Nordisk research grant and is the Chief Medical Officer and a shareholder of Reset Health Ltd.